temozolomide has been researched along with Osteogenic Sarcoma in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide/etoposide is a feasible candidate as salvage therapy for relapsed osteosarcoma." | 5.56 | Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma. ( Adachi, S; Akazawa, R; Arakawa, Y; Hiramatsu, H; Kato, I; Moritake, H; Okamoto, T; Saida, S; Sakamoto, A; Sumiyoshi, S; Takita, J; Umeda, K, 2020) |
| "In heavily pretreated patients with refractory/relapsed solid tumors, the vincristine, irinotecan, and temozolomide regimen seemed promising in Ewing sarcoma patients and was well tolerated." | 3.91 | Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience. ( Büyükkapu Bay, S; Çakır, FB; Darendeliler, E; Görgün, O; Kebudi, R; Zülfikar, B, 2019) |
| "We conducted a phase I and pharmacokinetic study of the epidermal growth factor receptor (EGFR) inhibitor erlotinib as a single agent and in combination with temozolomide in children with refractory solid tumors." | 2.73 | Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. ( Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD, 2008) |
| "Temozolomide/etoposide is a feasible candidate as salvage therapy for relapsed osteosarcoma." | 1.56 | Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma. ( Adachi, S; Akazawa, R; Arakawa, Y; Hiramatsu, H; Kato, I; Moritake, H; Okamoto, T; Saida, S; Sakamoto, A; Sumiyoshi, S; Takita, J; Umeda, K, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Umeda, K | 2 |
| Taura, K | 1 |
| Kato, I | 2 |
| Saida, S | 2 |
| Hiramatsu, H | 2 |
| Shimizu, H | 1 |
| Nakamoto, Y | 1 |
| Uto, M | 1 |
| Mizowaki, T | 1 |
| Sakamoto, A | 2 |
| Adachi, S | 2 |
| Okamoto, T | 2 |
| Takita, J | 2 |
| Yi, GZ | 1 |
| Zhu, TC | 1 |
| Que, TS | 1 |
| Li, ZY | 1 |
| Huang, GL | 1 |
| Akazawa, R | 1 |
| Arakawa, Y | 1 |
| Sumiyoshi, S | 1 |
| Moritake, H | 1 |
| Ju, HY | 1 |
| Park, M | 1 |
| Lee, JA | 1 |
| Park, HJ | 1 |
| Park, SY | 1 |
| Kim, JH | 1 |
| Kang, HG | 1 |
| Yang, HC | 1 |
| Park, BK | 1 |
| Büyükkapu Bay, S | 1 |
| Kebudi, R | 1 |
| Görgün, O | 1 |
| Zülfikar, B | 1 |
| Darendeliler, E | 1 |
| Çakır, FB | 1 |
| Jakacki, RI | 1 |
| Hamilton, M | 1 |
| Gilbertson, RJ | 1 |
| Blaney, SM | 1 |
| Tersak, J | 1 |
| Krailo, MD | 1 |
| Ingle, AM | 1 |
| Voss, SD | 1 |
| Dancey, JE | 1 |
| Adamson, PC | 1 |
| Niswander, LM | 1 |
| Kim, SY | 1 |
1 review available for temozolomide and Osteogenic Sarcoma
| Article | Year |
|---|---|
Stratifying osteosarcoma: minimizing and maximizing therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Dacarbazine; Humans; Integri | 2010 |
1 trial available for temozolomide and Osteogenic Sarcoma
| Article | Year |
|---|---|
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; | 2008 |
5 other studies available for temozolomide and Osteogenic Sarcoma
| Article | Year |
|---|---|
Intensive Multimodal Therapy Combined With Long-term Temozolomide and Etoposide Treatment for Recurrent Osteosarcoma to the Liver and Stomach.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined Modality Therapy; Et | 2022 |
Individualized combination therapies based on whole-exome sequencing displayed significant clinical benefits in a glioblastoma patient with secondary osteosarcoma: case report and genetic characterization.
Topics: Bone Neoplasms; Brain Neoplasms; Everolimus; Exome Sequencing; Female; Glioblastoma; Humans; Middle | 2022 |
Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2020 |
Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Female; Humans; Irinotecan; M | 2022 |
Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2019 |